Table of Contents 1 Disease-Modifying Antirheumatic Drug Market Overview 1.1 Product Overview and Scope of Disease-Modifying Antirheumatic Drug 1.2 Disease-Modifying Antirheumatic Drug Segment by Type 1.2.1 Global Disease-Modifying Antirheumatic Drug Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Non-Steroidal Anti-Inflammatory Drugs 1.2.3 Steroidal Anti-Inflammatory Drugs 1.2.4 Slow Acting Drug 1.2.5 Immunological Preparation 1.3 Disease-Modifying Antirheumatic Drug Segment by Application 1.3.1 Disease-Modifying Antirheumatic Drug Sales Comparison by Application: 2020 VS 2026 1.3.2 Pharmaceutical Industry 1.3.3 Hospital and Clinic 1.3.4 Other 1.4 Global Disease-Modifying Antirheumatic Drug Market Size Estimates and Forecasts 1.4.1 Global Disease-Modifying Antirheumatic Drug Revenue 2015-2026 1.4.2 Global Disease-Modifying Antirheumatic Drug Sales 2015-2026 1.4.3 Disease-Modifying Antirheumatic Drug Market Size by Region: 2020 Versus 2026 2 Global Disease-Modifying Antirheumatic Drug Market Competition by Manufacturers 2.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2015-2020) 2.2 Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020) 2.3 Global Disease-Modifying Antirheumatic Drug Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Disease-Modifying Antirheumatic Drug Manufacturing Sites, Area Served, Product Type 2.5 Disease-Modifying Antirheumatic Drug Market Competitive Situation and Trends 2.5.1 Disease-Modifying Antirheumatic Drug Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Disease-Modifying Antirheumatic Drug Players (Opinion Leaders) 3 Disease-Modifying Antirheumatic Drug Retrospective Market Scenario by Region 3.1 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country 3.3.1 North America Disease-Modifying Antirheumatic Drug Sales by Country 3.3.2 North America Disease-Modifying Antirheumatic Drug Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country 3.4.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country 3.4.2 Europe Disease-Modifying Antirheumatic Drug Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region 3.5.2 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country 3.6.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Country 3.6.2 Latin America Disease-Modifying Antirheumatic Drug Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country 3.7.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Disease-Modifying Antirheumatic Drug Historic Market Analysis by Type 4.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020) 4.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2015-2020) 4.3 Global Disease-Modifying Antirheumatic Drug Price Market Share by Type (2015-2020) 4.4 Global Disease-Modifying Antirheumatic Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Disease-Modifying Antirheumatic Drug Historic Market Analysis by Application 5.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020) 5.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2015-2020) 5.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2015-2020) 6 Company Profiles and Key Figures in Disease-Modifying Antirheumatic Drug Business 6.1 AbbVie 6.1.1 Corporation Information 6.1.2 AbbVie Description, Business Overview and Total Revenue 6.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.1.4 AbbVie Products Offered 6.1.5 AbbVie Recent Development 6.2 Amgen 6.2.1 Amgen Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.2.2 Amgen Description, Business Overview and Total Revenue 6.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Amgen Products Offered 6.2.5 Amgen Recent Development 6.3 Pfizer 6.3.1 Pfizer Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.3.2 Pfizer Description, Business Overview and Total Revenue 6.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Pfizer Products Offered 6.3.5 Pfizer Recent Development 6.4 Roche Holding AG 6.4.1 Roche Holding AG Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.4.2 Roche Holding AG Description, Business Overview and Total Revenue 6.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Roche Holding AG Products Offered 6.4.5 Roche Holding AG Recent Development 6.5 Novartis International AG 6.5.1 Novartis International AG Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.5.2 Novartis International AG Description, Business Overview and Total Revenue 6.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Novartis International AG Products Offered 6.5.5 Novartis International AG Recent Development 6.6 Johnson & Johnson 6.6.1 Johnson & Johnson Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.6.2 Johnson & Johnson Description, Business Overview and Total Revenue 6.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Johnson & Johnson Products Offered 6.6.5 Johnson & Johnson Recent Development 6.7 Bristol-Myers Squibb 6.6.1 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.6.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue 6.6.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Bristol-Myers Squibb Products Offered 6.7.5 Bristol-Myers Squibb Recent Development 6.8 Merck 6.8.1 Merck Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.8.2 Merck Description, Business Overview and Total Revenue 6.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Merck Products Offered 6.8.5 Merck Recent Development 6.9 UCB S.A. 6.9.1 UCB S.A. Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.9.2 UCB S.A. Description, Business Overview and Total Revenue 6.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.9.4 UCB S.A. Products Offered 6.9.5 UCB S.A. Recent Development 6.10 Eli Lilly and Company 6.10.1 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Production Sites and Area Served 6.10.2 Eli Lilly and Company Description, Business Overview and Total Revenue 6.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020) 6.10.4 Eli Lilly and Company Products Offered 6.10.5 Eli Lilly and Company Recent Development 7 Disease-Modifying Antirheumatic Drug Manufacturing Cost Analysis 7.1 Disease-Modifying Antirheumatic Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug 7.4 Disease-Modifying Antirheumatic Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Disease-Modifying Antirheumatic Drug Distributors List 8.3 Disease-Modifying Antirheumatic Drug Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Disease-Modifying Antirheumatic Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Disease-Modifying Antirheumatic Drug by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Disease-Modifying Antirheumatic Drug by Type (2021-2026) 10.2 Disease-Modifying Antirheumatic Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Disease-Modifying Antirheumatic Drug by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Disease-Modifying Antirheumatic Drug by Application (2021-2026) 10.3 Disease-Modifying Antirheumatic Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Disease-Modifying Antirheumatic Drug by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Disease-Modifying Antirheumatic Drug by Region (2021-2026) 10.4 North America Disease-Modifying Antirheumatic Drug Estimates and Projections (2021-2026) 10.5 Europe Disease-Modifying Antirheumatic Drug Estimates and Projections (2021-2026) 10.6 Asia Pacific Disease-Modifying Antirheumatic Drug Estimates and Projections (2021-2026) 10.7 Latin America Disease-Modifying Antirheumatic Drug Estimates and Projections (2021-2026) 10.8 Middle East and Africa Disease-Modifying Antirheumatic Drug Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Disease-Modifying Antirheumatic Drug Sales (MT) Growth Rate Comparison by Type (2015-2026) Table 2. Global Disease-Modifying Antirheumatic Drug Sales (MT) Comparison by Application: 2020 VS 2026 Table 3. Global Disease-Modifying Antirheumatic Drug Market Size by Type (MT) (US$ Million) (2020 VS 2026) Table 4. Global Key Disease-Modifying Antirheumatic Drug Manufacturers Covered in This Study Table 5. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Manufacturers (2015-2020) Table 6. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers (2015-2020) Table 7. Global Disease-Modifying Antirheumatic Drug Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Disease-Modifying Antirheumatic Drug Average Price (USD/MT) of Key Manufacturers (2015-2020) Table 10. Manufacturers Disease-Modifying Antirheumatic Drug Sales Sites and Area Served Table 11. Manufacturers Disease-Modifying Antirheumatic Drug Product Types Table 12. Global Disease-Modifying Antirheumatic Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2019) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Disease-Modifying Antirheumatic Drug Players Table 16. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Region (2015-2020) Table 17. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020) Table 18. Global Disease-Modifying Antirheumatic Drug Revenue (Million US$) by Region (2015-2020) Table 19. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020) Table 20. North America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT) Table 21. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020) Table 22. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million) Table 23. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020) Table 24. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT) Table 25. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020) Table 26. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2015-2020) (MT) Table 29. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020) Table 32. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT) Table 33. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020) Table 34. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT) Table 37. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020) Table 40. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020) Table 41. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2015-2020) Table 42. Global Disease-Modifying Antirheumatic Drug Revenue (Million US$) by Type (2015-2020) Table 43. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2015-2020) Table 44. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Type (2015-2020) Table 45. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020) Table 46. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020) Table 47. Global Disease-Modifying Antirheumatic Drug Sales Growth Rate by Application (2015-2020) Table 48. AbbVie Disease-Modifying Antirheumatic Drug Corporation Information Table 49. AbbVie Description and Business Overview Table 50. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 51. AbbVie Main Product Table 52. AbbVie Recent Development Table 53. Amgen Disease-Modifying Antirheumatic Drug Corporation Information Table 54. Amgen Corporation Information Table 55. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 56. Amgen Main Product Table 57. Amgen Recent Development Table 58. Pfizer Disease-Modifying Antirheumatic Drug Corporation Information Table 59. Pfizer Corporation Information Table 60. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 61. Pfizer Main Product Table 62. Pfizer Recent Development Table 63. Roche Holding AG Disease-Modifying Antirheumatic Drug Corporation Information Table 64. Roche Holding AG Corporation Information Table 65. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 66. Roche Holding AG Main Product Table 67. Roche Holding AG Recent Development Table 68. Novartis International AG Disease-Modifying Antirheumatic Drug Corporation Information Table 69. Novartis International AG Corporation Information Table 70. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 71. Novartis International AG Main Product Table 72. Novartis International AG Recent Development Table 73. Johnson & Johnson Disease-Modifying Antirheumatic Drug Corporation Information Table 74. Johnson & Johnson Corporation Information Table 75. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 76. Johnson & Johnson Main Product Table 77. Johnson & Johnson Recent Development Table 78. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Corporation Information Table 79. Bristol-Myers Squibb Corporation Information Table 80. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 81. Bristol-Myers Squibb Main Product Table 82. Bristol-Myers Squibb Recent Development Table 83. Merck Disease-Modifying Antirheumatic Drug Corporation Information Table 84. Merck Corporation Information Table 85. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 86. Merck Main Product Table 87. Merck Recent Development Table 88. UCB S.A. Disease-Modifying Antirheumatic Drug Corporation Information Table 89. UCB S.A. Corporation Information Table 90. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 91. UCB S.A. Main Product Table 92. UCB S.A. Recent Development Table 93. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Corporation Information Table 94. Eli Lilly and Company Corporation Information Table 95. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 96. Eli Lilly and Company Main Product Table 97. Eli Lilly and Company Recent Development Table 98. Sales Base and Market Concentration Rate of Raw Material Table 99. Key Suppliers of Raw Materials Table 100. Disease-Modifying Antirheumatic Drug Distributors List Table 101. Disease-Modifying Antirheumatic Drug Customers List Table 102. Market Key Trends Table 103. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 104. Key Challenges Table 105. Global Disease-Modifying Antirheumatic Drug Sales (MT) Forecast by Type (2021-2026) Table 106. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Type (2021-2026) Table 107. Global Disease-Modifying Antirheumatic Drug Revenue (Million US$) Forecast by Type (2021-2026) Table 108. Global Disease-Modifying Antirheumatic Drug Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 109. Global Disease-Modifying Antirheumatic Drug Sales (MT) Forecast by Application (2021-2026) Table 110. Global Disease-Modifying Antirheumatic Drug Revenue (Million US$) Forecast by Application (2021-2026) Table 111. Global Disease-Modifying Antirheumatic Drug Sales (MT) Forecast by Region (2021-2026) Table 112. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Region (2021-2026) Table 113. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2021-2026) (US$ Million) Table 114. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Region (2021-2026) Table 115. Research Programs/Design for This Report Table 116. Key Data Information from Secondary Sources Table 117. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Disease-Modifying Antirheumatic Drug Figure 2. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type: 2020 VS 2026 Figure 3. Non-Steroidal Anti-Inflammatory Drugs Product Picture Figure 4. Steroidal Anti-Inflammatory Drugs Product Picture Figure 5. Slow Acting Drug Product Picture Figure 6. Immunological Preparation Product Picture Figure 7. Global Disease-Modifying Antirheumatic Drug Consumption Market Share by Application: 2020 VS 2026 Figure 8. Pharmaceutical Industry Figure 9. Hospital and Clinic Figure 10. Other Figure 11. Global Disease-Modifying Antirheumatic Drug Market Size 2015-2026 (US$ Million) Figure 12. Global Disease-Modifying Antirheumatic Drug Sales Capacity (MT) (2015-2026) Figure 13. Global Disease-Modifying Antirheumatic Drug Market Size Market Share by Region: 2020 Versus 2026 Figure 14. Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers in 2020 Figure 15. Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers in 2019 Figure 16. The Global 5 and 10 Largest Players: Market Share by Disease-Modifying Antirheumatic Drug Revenue in 2019 Figure 17. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 18. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020) Figure 19. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019 Figure 20. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020) Figure 21. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019 Figure 22. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019 Figure 23. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019 Figure 24. U.S. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 25. U.S. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 26. Canada Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 27. Canada Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 28. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019 Figure 29. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019 Figure 30. Germany Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 31. Germany Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 32. France Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 33. France Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 34. U.K. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 35. U.K. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. Italy Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 37. Italy Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 38. Russia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 39. Russia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 40. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019 Figure 41. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019 Figure 42. China Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 43. China Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 44. Japan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 45. Japan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. South Korea Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 47. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. India Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 49. India Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Australia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 51. Australia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Taiwan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 53. Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. Indonesia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 55. Indonesia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. Thailand Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 57. Thailand Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Malaysia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 59. Malaysia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Philippines Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 61. Philippines Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Vietnam Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 63. Vietnam Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019 Figure 65. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019 Figure 66. Mexico Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 67. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Brazil Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 69. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Argentina Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 71. Argentina Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019 Figure 73. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019 Figure 74. Turkey Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 75. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Saudi Arabia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 77. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. U.A.E Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT) Figure 79. U.A.E Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Sales Market Share of Disease-Modifying Antirheumatic Drug by Type (2015-2020) Figure 81. Sales Market Share of Disease-Modifying Antirheumatic Drug by Type in 2019 Figure 82. Revenue Share of Disease-Modifying Antirheumatic Drug by Type (2015-2020) Figure 83. Revenue Market Share of Disease-Modifying Antirheumatic Drug by Type in 2019 Figure 84. Global Disease-Modifying Antirheumatic Drug Sales Growth by Type (2015-2020) (MT) Figure 85. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020) Figure 86. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019 Figure 87. Global Revenue Share of Disease-Modifying Antirheumatic Drug by Application (2015-2020) Figure 88. Global Revenue Share of Disease-Modifying Antirheumatic Drug by Application in 2020 Figure 89. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018 Figure 90. Amgen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 91. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 92. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. Novartis International AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Merck Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. UCB S.A. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 98. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 99. Price Trend of Key Raw Materials Figure 100. Manufacturing Cost Structure of Disease-Modifying Antirheumatic Drug Figure 101. Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug Figure 102. Disease-Modifying Antirheumatic Drug Industrial Chain Analysis Figure 103. Channels of Distribution Figure 104. Distributors Profiles Figure 105. Porter's Five Forces Analysis Figure 106. North America Disease-Modifying Antirheumatic Drug Sales (MT) and Growth Rate Forecast (2021-2026) Figure 107. North America Disease-Modifying Antirheumatic Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 108. Europe Disease-Modifying Antirheumatic Drug Sales (MT) and Growth Rate Forecast (2021-2026) Figure 109. Europe Disease-Modifying Antirheumatic Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 110. Latin America Disease-Modifying Antirheumatic Drug Sales (MT) and Growth Rate Forecast (2021-2026) Figure 111. Latin America Disease-Modifying Antirheumatic Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 112. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales (MT) and Growth Rate Forecast (2021-2026) Figure 113. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 114. Asia Pacific Disease-Modifying Antirheumatic Drug Sales (MT) and Growth Rate Forecast (2021-2026) Figure 115. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 116. Bottom-up and Top-down Approaches for This Report Figure 117. Data Triangulation Figure 118. Key Executives Interviewed

AbbVie Amgen Pfizer Roche Holding AG Novartis International AG Johnson & Johnson Bristol-Myers Squibb Merck UCB S.A. Eli Lilly and Company